GG
PEAR

Gleason Group’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Gleason Group’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,250
Closed -$9K – 241
2022
Q3 		$9K Hold
4,250
– – ﹤0.01% 184
2022
Q2 		$7K Hold
4,250
– – ﹤0.01% 186
2022
Q1 		$21K Buy
+4,250
New +$19.3K 0.01% 152

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return

Gleason Group's PEAR Position: Q4 2022 in Review

Gleason Group sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q4 2022, closing a stake of 4,250 shares — an estimated $9K sold.

Gleason Group first reported a position in PEAR in Q1 2022 and held it in 3 quarters. The position peaked at $21K in Q1 2022. 64 funds tracked by Wall St. Rank hold PEAR as of Q4 2022.

  • Gleason Group reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
  • Gleason Group sold 4,250 Pear Therapeutics, Inc. Class A Common Stock shares in Q4 2022, an estimated $9K.
  • Gleason Group first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 3 quarters.
  • Gleason Group's Pear Therapeutics, Inc. Class A Common Stock position peaked at $21K in Q1 2022.
  • 64 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q4 2022.

Based on Gleason Group's 13F filing for Q4 2022, filed 11 Jan 2023.